Another productive and exciting week for RevOpsis Therapeutics in Stockholm at the annual ASRS – American Society of Retina Specialists meeting. A special thanks to Subhransu Ray for presenting the Preclinical Analysis of a Novel #Trispecific Antibody, RO-104, for Use in Retinal Neovascular Disease. We appreciate everyone who facilitated this abstract and are looking forward to our next data release. Stay tuned! Ramanath Bhandari, Ram Palanki, Ronil Patel, Ramesh R. Bhatt, Li Xu, Jessi Prentice, Arshad M. Khanani, Jeff Heier, Mark Barakat, MD, Peter Kaiser
RevOpsis Therapeutics’ Post
More Relevant Posts
-
We’re thrilled to announce the first patient dosed in our second clinical program, a Phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 for advanced solid tumors. This milestone reflects our continued commitment to advancing innovative therapies for patients with unmet needs. #HealthcareInnovation #ClinicalTrials #Biotechnology https://lnkd.in/gbmZ7nep
-
Join us on November 13th for a rebroadcast of the 2024 IO360º debate. This year's debate focused on the next-generation approaches that might solve some of the biggest challenges in immuno-oncology. More specifically, the participants debated: • Whether cell therapy or bispecific engagers were the better option for treatment, toxicity and persistence • Which IO therapies (for example, in vivo CAR T therapy) will lead to the next big step change for the IO landscape • Which therapies will ultimately be the most successful in solid tumors • Combination therapies (including PD-1 and T cell engagers), and more Moderated by William Ho, IN8bio, panelists include: - Dr Charles Drake, Johnson & Johnson Innovative Medicine - Dr Kristen Hege, Adaptimmune, Mersana Therapeutics, and Graphite Bio - Dr Axel Hoos, former CEO, Scorpion Therapeutics - Dr Michael Kalos, Next Pillar Consulting - Dr Naiyer Rizvi, Synthekine - Dr Alex Snyder, Generate:Biomedicines. Register here: https://lnkd.in/giXmg9eS #IO360Summit #immunooncology #clinicaltrials ##clinicalresearch
-
-
An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models | https://lnkd.in/gu9AyiXH RLY-2608 is an oral, mutant-selective PI3Kα allosteric inhibitor from Relay Therapeutics, targeting a cryptic pocket near the ATP-binding site. Given the challenges and toxicities associated with WT PI3Kα inhibition—such as hyperglycemia and rash—there's an increasing need for next-generation, mutant-selective PI3Kα inhibitors. Relay Therapeutics recently shared promising interim data from the Phase I ReDiscover trial in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer. Explore this case study on RLY-2608 to dive into the discovery strategy, mechanisms driving mutant selectivity, its position in the competitive landscape, preclinical activity, recent clinical developments, and more. Full Article: https://lnkd.in/gu9AyiXH
-
The dynamic needs of your preclinical and translational studies require innovative technologies grounded in science, driven by data. Our end-to-end services use the most advanced analysis and generate comprehensive data, utilizing machine intelligence to help you make better-informed decisions. ✅OrganoidXploreᵀᴹ is our large-scale organoid panel screening platform providing robust, reproducible, and clinically relevant results. ✅SynAI is our AI-driven platform designed to predict the synergistic effects of cancer drug combinations, trained with over 1.2 million in vitro tests. ✅Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies, with seamless delivery. ✅We provide certified CRO services using NanoString's GeoMx® platform to efficiently address tissue diversity and intricate micro-environments. Learn more➡️ https://hubs.la/Q02WPT0L0
-
-
Today, we will present preclinical data supporting the development of ziftomenib for the treatment of advanced gastrointestinal stromal tumors (#GIST) at the EORTC-NCI-AACR Symposium. These new findings highlight the potential of #ziftomenib in combination with KIT inhibitors, including the frontline standard of care imatinib, for the treatment of patients with advanced GIST. Learn more about the data and access the full poster: https://bit.ly/48mvloz #ENASymp24
-
Very promising step with POLQ inhibitor!
We are one step closer to potentially improving the lives of patients with the first patient dosed with RP-3467, our potential best-in-class Polθ ATPase inhibitor. RP-3467 has demonstrated highly compelling preclinical results, including complete and durable tumor regressions in combination with olaparib with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, an area of high unmet medical need. Learn more here: https://lnkd.in/ebSbQbAy #precisiononcology
-
Business Development Manager @ Cypre Inc. | Driving Sales Growth with Marketing Expertise
Get predictive datasets for therapeutic efficacy and MOA in weeks not months! DM me to start a discussion about your study today!
The Cypre 42 Panel - 3D Immuno-oncology models delivering predictive datasets for therapeutic efficacy and MOA in the tumor microenvironment. Learn more on our website: https://lnkd.in/g9caafvJ Cypre Inc. Charles River Laboratories
-
-
The annual debate at the 2024 IO360º Summit focused on the next-generation approaches that might solve some of the biggest challenges in immuno-oncology. More specifically, the participants debated: • Whether cell therapy or bispecific engagers were the better option for treatment, toxicity and persistence • Which IO therapies (for example, in vivo CAR T therapy) will lead to the next big step change for the IO landscape • Which therapies will ultimately be the most successful in solid tumors • Combination therapies (including PD-1 and T cell engagers), and more Moderated by William Ho, IN8bio, panelists include: • Dr Charles Drake, Johnson & Johnson Innovative Medicine • Dr Kristen Hege, Adaptimmune, Mersana Therapeutics, and Graphite Bio • Dr @Axel Hoos, former CEO, Scorpion Therapeutics • Dr Michael Kalos, Next Pillar Consulting • Dr Naiyer Rizvi, Synthekine • Dr Alex Snyder, Generate:Biomedicines Listen to the debate here: https://lnkd.in/gMydQ9Xm #IO360Summit #immunooncology #clinicaltrials ##clinicalresearch
-
-
Artiva Biotherapeutics Upsizes IPO to $167M, Lists on Nasdaq Today Artiva Biotherapeutics has increased its IPO to $167 million and is set to list on Nasdaq under the symbol "ARTV" today. The funds will support the clinical development of AlloNK, a cryopreserved NK cell therapy currently in phase 1 trials for lupus nephritis. This exciting development in NK cell therapy holds promise for advancing treatment options for autoimmune diseases. At Biocytogen, we offer advanced humanized mouse models for autoimmune diseases to support your preclinical research and development needs. Check out our autoimmune related mouse model here: https://lnkd.in/ea4ny3UG #Biotech #IPO #ArtivaBiotherapeutics #NKCellTherapy #AutoimmuneResearch #Biocytogen
-
-
Wonder what we are up to at MOMA? We are focused on highly dynamic proteins. Learn more below
MOMA's mission is all about harnessing the power of highly dynamic proteins - but what are they? Highly dynamic proteins - often referred to as "molecular machines” - drive many cellular processes that underlie human disease. They are historically hard to drug because of their ability to shapeshift. We're focusing on the potential of this target class with two wholly-owned lead oncology assets, alongside a strong pipeline of high-value pre-clinical candidates so we can bring a new generation of precision therapeutics to patients in need. Learn more about highly dynamic proteins below and at momatx.com.
